Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Sign in
Join now
Eric Jonasch MD

Eric Jonasch MD

Professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine; Director, VHL Clinical Center, The University of Texas MD Anderson Cancer Center, Houston, Texas

Biographical Sketch:

Eric Jonasch is Professor in the Department of Genitourinary Medical Oncology, Division of Cancer Medicine, at the MD Anderson Cancer Center of The University of Texas in Houston, where he is also Co-Chair of the Renal Cancer Program. Since 2003, Dr. Jonasch has been the Director of the Von Hippel Lindau (VHL) Clinical Center in Houston. He performs clinical, translational, and basic research in VHL disease and kidney cancer.

After receiving his MDCM degree from McGill University Faculty of Medicine, Dr. Jonasch underwent clinical residency in internal medicine at the Royal Victoria Hospital in Montreal. Subsequently, he completed a clinical fellowship in Hematology/Oncology at the New England Medical Center in Boston, as well as a research fellowship. He was then awarded a research fellowship at the Beth Israel Deaconess Medical Center in Boston.

Dr. Jonasch is a member of the American Association for Cancer Research, the American Society of Clinical Oncology, and is vice chair of the National Comprehensive Cancer Network kidney cancer guidelines. Additionally, Dr. Jonasch has published widely in many peer-reviewed journals and has contributed to and published various books.

Positions:
Professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, MD Anderson Cancer Center
Director, VHL Clinical Center, MD Anderson Cancer Center
Co-Chair, Renal Cancer Program, MD Anderson Cancer Center

Consultantships:
Vice Chair, Kidney Cancers Panel, National Comprehensive Cancer Network

Degree:
McGill University Faculty of Medicine, MDCM

Postgraduate Training:
Postdoctoral research fellow, Beth Israel Deaconess Medical Center, Boston
Postdoctoral clinical fellow, New England Medical Center, Boston

Board Certifications:
Medical Oncology, American Board of Internal Medicine
Oncology, Royal College of Physicians & Surgeons of Canada
Medicine, Royal College of Physicians & Surgeons of Canada
Hematology, American Board of Internal Medicine
Internal Medicine, American Board of Internal Medicine

Disclosures

Eric Jonasch, MD, serves as a consultant to Aravive, Aveo, BMS, Calithera, Eisai, Exelixis, Ipsen, Merck Inc, NiKang, Pfizer Inc, Novartis AG and has received research/grant support from Merck Inc NiKang, Novartis AG and Telix.

Recent Contributions to PracticeUpdate:

  1. Updated Results of Belzutifan for Advanced RCC
  2. Health-Related Quality of Life and Clinical Outcomes in Advanced RCC
  3. ASCO 2022: Abstract Recommendations From Dr. Eric Jonasch for Kidney and Bladder Cancer
  4. Pembrolizumab as Post-Nephrectomy Adjuvant Therapy for Renal Cell Carcinoma
  5. Nivolumab Followed By Salvage Nivolumab Plus Ipilimumab for Treatment-Naive Patients With Advanced RCC
  6. Healthcare Resource Utilization and Costs Among Patients With VHL-Associated RCC
  7. 2021 Top Story in VHL Disease: FDA Approval of Belzutifan for VHL-Associated RCC
  8. Hemangioblastoma Diagnosis and Surveillance in VHL Disease
  9. Belzutifan FDA Approval for VHL-Associated Cancers
  10. Cytoreductive Nephrectomy and Aggressive Histology in mRCC

Most Read This Week

Recently Updated